Tuberc Respir Dis > Volume 64(2); 2008 > Article
Tuberculosis and Respiratory Diseases 2008;64(2):102-108.
DOI:    Published online February 1, 2008.
A Trial of Aerosolized Colistin for the Treatment of Nosocomial Pneumonia due to Multidrug-resistant Acinetobacter baumannii.
Changhwan Kim, Dong Gyu Kim, Hye Ryun Kang, Jeong Hee Choi, Chang Youl Lee, Yong Il Hwang, Tae Rim Shin, Sang Myeon Park, Yong Bum Park, Jae Young Lee, Seung Hun Jang, Cheol Hong Kim, Eun Kyung Mo, Myung Goo Lee, In Gyu Hyun, Ki Suck Jung, Young Jin Choi, Jae Woong Lee
1Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Korea.
2Department of Thoracic & Cardiovascular Surgery, Hallym University College of Medicine, Chuncheon, Korea.
Recently, multidrug-resistant (MDR) A. baumannii has been implicated for a significant proportion of nosocominal pneumonia in many intensive care units (ICUs), and its acquisition may increase mortality and the length of stay in the ICU. Aerosolized colistin has been successfully used in patients with cystic fibrosis, but there is a lack of data regarding the use of aerosolized colistin in patients with nosocomial pneumonia. METHODS: We conducted the present study to assess the effectiveness of aerosolized colistin for the treatment of MDR A. baumannii nosocomial pneumonia. We retrospectively reviewed the medical records of 10 patients who had been hospitalized in the medical ICU and had received aerosolized colistin as a therapy for MDR A. baumannii pneumonia. RESULTS: The mean duration of aerosolized colistin therapy was 12.7+/-2.4 days. Nine (90%) of 10 patients showed a favorable response to the therapy. Follow-up cultures were available for all patients, and the responsible pathogen was completely eradicated. One patient suffered from bronchospasm, which resolved after treatment with nebulized salbutamol. CONCLUSION: Our results corroborate previous reports that aerosolized colistin may be an effective and safe choice for the treatment of nosocomial pneumonia caused by MDR A. baumannii. Larger prospective controlled clinical studies are warranted to validate further the effectiveness and safety of aerosolized colistin therapy.
Key Words: Acinetobacter baumannii, Aerosolized colistin, Nosocomial pneumonia

Article category

Browse all articles >


Browse all articles >

Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail:                

Copyright © 2024 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2PI

Close layer
prev next